DSS · Dss, Inc.

On March 26, 2026 the Issuer issued common stock purchase warrants (the "Warrants") to Alset International Limited to purchase up to 16,554,055 shares of the Issuer's common stock at an exercise price of $0.93 per share. The Warrants expire on March 26, 2031.

The beneficial ownership of Mr. Chan as of the date hereof may be deemed to include the following shares held personally (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of the Issuer's common stock held by Mr. Chan directly.

Mr. Chan may also be deemed to beneficially own (a) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (b) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (c) 1,068,309 shares of the Issuer's common stock, a convertible promissory note in the amount of $2,450,000, and common stock purchase warrants to purchase up to 16,554,055 shares held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (d) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

On March 26, 2026 the Issuer issued a convertible promissory note (the "Convertible Promissory Note") to Alset International Limited in the amount of $2,450,000, which became convertible on June 3, 2026. Under the terms of the Convertible Promissory Note, Alset International Limited may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of either (i) $0.74 per share, or (ii) if while the Convertible Promissory Note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the Convertible Promissory Note, the Holder may elect to exchange the Convertible Promissory Note for such convertible instrument based on the Convertible Promissory Note's principal balance plus any accrued but unpaid interest.

The beneficial ownership of Mr. Chan as of the date hereof may be deemed to include the following shares held personally (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of the Issuer's common stock held by Mr. Chan directly.

Mr. Chan may also be deemed to beneficially own (a) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (b) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (c) 1,068,309 shares of the Issuer's common stock, a convertible promissory note in the amount of $2,450,000, and common stock purchase warrants to purchase up to 16,554,055 shares held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (d) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

On August 28, 2025, Mr. Chan sold 130,679 shares of the Issuer's common stock at an average sale price of $1.3475. The shares were sold in multiple trades at prices ranging between $1.23 and $1.565. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Mr. Chan may be deemed to include the following: (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,053,796 shares of the Issuer's common stock held by Mr. Chan directly; (c) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (e) 1,068,309 shares of the Issuer's common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (f) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

This Amended Form 4 is being filed to clarify certain information set forth on the Form 4 originally filed by the reporting persons on August 22, 2025.

On August 20, 2025, the Issuer issued a convertible promissory note (the "Convertible Promissory Note") to Alset Inc. in the amount of $500,000. Under the terms of the Convertible Promissory Note, Alset Inc. may convert outstanding principal and interest into shares of the Issuer's common stock at a conversion price of either (i) $0.86 per share, or (ii) if while the Convertible Promissory Note is outstanding, the Issuer sells or issues any other convertible instruments on terms that differ from the Convertible Promissory Note, the Holder may elect to exchange the Convertible Promissory Note for such convertible instrument based on the Convertible Promissory Note's principal balance plus any accrued but unpaid interest.

The beneficial ownership of Mr. Chan as of August 22, 2025 may be deemed to include the following (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of the Issuer's common stock held by Mr. Chan directly; (c) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (e) 1,068,309 shares of the Issuer's common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (f) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

On February 6, 2025, the Issuer awarded Mr. Heng Fai Ambrose Chan, a Director of the Company, a stock grant of 1,000,000 newly issued shares of the Issuer's common stock through his personally owned company, Heng Fai Holdings Limited as compensation for services rendered. The common stock was issued pursuant to the Issuer's 2020 Employee, Director and Consultant Equity Incentive Plan.

The beneficial ownership of Mr. Chan includes a total of 6,148,664 shares of common stock, consisting of (a) 1,002,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

On December 10, 2024, Alset Inc. entered into a stock purchase agreement with DSS, Inc. (the "Issuer"), pursuant to which Alset Inc. agreed to purchase 820,597 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Alset Inc. and its various subsidiaries are collectively the largest shareholder of DSS. Further, on December 10, 2024, Mr. Chan directly entered into a stock purchase agreement with the Issuer, pursuant to which he agreed to purchase 205,149 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Mr. Chan is the Executive Chairman of DSS.

The beneficial ownership of Mr. Chan includes a total of 5,148,664 shares of common stock, consisting of (a) 2,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

On December 10, 2024, Alset Inc. entered into a stock purchase agreement with DSS, Inc. (the "Issuer"), pursuant to which Alset Inc. agreed to purchase 820,597 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Alset Inc. and its various subsidiaries are collectively the largest shareholder of DSS. Further, on December 10, 2024, Mr. Chan directly entered into a stock purchase agreement with the Issuer, pursuant to which he agreed to purchase 205,149 newly issued shares of the Issuer's common stock for a purchase price of $0.9749 per share. Mr. Chan is the Executive Chairman of DSS.

The beneficial ownership of Mr. Chan includes a total of 5,148,664 shares of common stock, consisting of (a) 2,978 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,184,475 shares of common stock held by Mr. Chan directly; (c) 2,581,268 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 1,068,309 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 311,634 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).

Owned and sold by Mr. Wu's spouse. Mr. Wu disclaimed beneficial ownership of these securities.

On December 28, 2023, the reporting person purchased 672,173 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1239 to $0.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Heng Fai Chan includes a total of 82,458,315 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 19,586,499 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 21,366,177 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited.

On April 10, 2023, Frank D. Heuszel was issued 1,247,078 shares of common stock pursuant to his employment agreement.

On December 13, 2022, the reporting person purchased 334,921 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1899 to $0.25. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Heng Fai Chan includes a total of 81,786,142 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 18,914,326 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc.; (d) 21,366,177 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.

On December 9, 2022, the reporting person purchased 51,385 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1866 to $0.195. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

The beneficial ownership of Heng Fai Chan includes a total of 81,451,221 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 18,579,405 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc.; (d) 21,366,177 shares of common stock held by Alset International Limited, a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of Alset International Limited. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset Inc., Alset International Limited and Global Biomedical Pte. Ltd.

On July 12, 2022, Alset International Limited ("AIL"), a majority owned subsidiary of Alset EHome International Inc. ("AEI"), was issued 21,366,177 shares of the common stock of DSS, Inc. (the "Issuer") pursuant to an assignment and assumption agreement (the "Agreement") between the Issuer and AIL dated February 25, 2022, as amended on July 12, 2022. Pursuant to the Agreement, as amended, the Issuer agreed to purchase a convertible promissory note from AIL (the "Note"). The Note has a principal amount of $8,350,000 and accrued but unpaid interest of $367,400. The Note was issued by American Medical REIT, Inc., a Maryland corporation. The consideration paid for the Note was 21,366,177 shares of the Issuer's common stock. The consideration was calculated by dividing $8,717,400, the aggregate of the principal amount and the accrued but unpaid interest under the Note, by $0.408 per share.

The beneficial ownership of Heng Fai Chan includes 81,399,836 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 16,973,020 shares of common stock held by Heng Fai Chan directly; (c) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., a subsidiary of AIL; (d) 35,213,416 shares of common stock held by Alset EHome International Inc.; and (e) 21,366,177 shares of common stock held by AIL, a subsidiary of Alset EHome International Inc. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset EHome International Inc., Global Biomedical Pte. Ltd., and Alset International Limited.

On July 7, 2022, Alset EHome International Inc. ("AEI") was issued 17,570,948 shares of common stock pursuant to a Stock Purchase Agreement ("SPA") between the Issuer and AEI dated February 28, 2022. Pursuant to the SPA, AEI agreed to sell a subsidiary holding 44,808,908 shares of stock of True Partner Capital Holding Limited, together with an additional 17,314,000 shares of True Partner Capital Holding Limited (for a total of 62,122,908 shares) in exchange for the 17,570,948 shares of the Issuer's common stock.

The beneficial ownership of Heng Fai Chan includes 60,033,659 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 16,973,020 shares of common stock held by Heng Fai Chan directly; (c) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd.; and (d) 35,213,416 shares of common stock held by Alset EHome International Inc. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset EHome International Inc. and Global Biomedical Pte. Ltd. Global Biomedical Pte. Ltd. is a subsidiary of an entity which is majority-owned by Alset EHome International Inc.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

Based on price at market close. The average purchase price for 140,000 shares was $0.4136.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

Based on price at market close. The average purchase price for 140,000 shares was $0.4136.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

Based on price at market close. The average purchase price for 140,000 shares was $0.4136.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

Based on price at market close. The average purchase price for 140,000 shares was $0.4136.

Owned and purchased by Mr. Wu's spouse. Mr. Wu disclaims beneficial ownership of these securities.

On May 25, 2022, Heng Fai Ambrose Chan was issued 15,389,995 shares of common stock pursuant to his employment agreement. Such shares were issued as payment of base salary and a performance bonus due under such employment agreement.

The beneficial ownership of Heng Fai Ambrose Chan includes 42,462,711 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Ambrose Chan; (b) 16,973,020 shares of common stock held by Heng Fai Ambrose Chan directly; (c) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd.; and (d) 17,642,468 shares of common stock held by Alset EHome International Inc.

On May 4, 2022, Frank D. Heuszel was issued 63,205 shares of common stock pursuant to his employment agreement. Such shares were issued as payment of a performance bonus due under such employment agreement.

On April 1, 2022, Heng Fai Chan was issued 894,084 shares of common stock pursuant to his employment agreement. Such shares were issued in consideration of $339,752 due under such employment agreement.

The beneficial ownership of Heng Fai Chan includes 27,072,716 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,583,025 shares of common stock held by Heng Fai Chan directly; (c) 16,667 shares of common stock held by BMI Capital Partners International Limited; (d) 7,716,004 shares of common stock held by Global Biomedical Pte. Ltd.; and (e) 16,142,468 shares of common stock held by Alset EHome International Inc.

The beneficial ownership of Heng Fai Chan includes 26,178,632 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 688,941 shares of common stock held by Heng Fai Chan directly; (c) 16,667 shares of common stock held by BMI Capital Partners International Limited; (d) 7,716,004 shares of common stock held by Global Biomedical Pte. Ltd.; and (e) 16,142,468 shares of common stock held by Alset EHome International Inc.

16,142,468 shares of common stock are owned directly by Alset EHome International Inc., including 3,986,877 shares purchased on March 9, 2022 pursuant to an agreement entered into between Alset EHome International Inc. and DSS, Inc. on February 28, 2022. Mr. Chan, as indirect beneficial owner, has dispositive control over the securities of the Issuer owned by Alset EHome International Inc., BMI Capital Partners International Limited and Global Biomedical Pte. Ltd. BMI Capital Partners International Limited and Global Biomedical Pte. Ltd. are each subsidiaries of entities majority-owned by Alset EHome International Inc.

The beneficial ownership of Heng Fai Chan includes 22,191,755 shares of common stock, consisting of (a) 1,614,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 688,941 shares of common stock held by Heng Fai Chan directly; (c) 16,667 shares of common stock held by BMI Capital Partners International Limited; (d) 7,716,004 shares of common stock held by Global Biomedical Pte. Ltd.; and (e) 12,155,591 shares of common stock held by Alset EHome International Inc.

These 12,155,591 shares of common stock are owned directly by Alset EHome International Inc. Mr. Chan has dispositive control over the securities of the Issuer owned by Alset EHome International Inc., BMI Capital Partners International Limited and Global Biomedical Pte. Ltd. BMI Capital Partners International Limited and Global Biomedical Pte. Ltd. are each subsidiaries of entities majority-owned by Alset EHome International Inc.

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the Common Stock of the Issuer at a conversion price of $6.48 per share. Following the conversion of 7,259 shares of Series A Convertible Preferred Stock, GBM does not own any shares of Series A Convertible Preferred Stock. Mr. Chan has dispositive control over the securities owned by GBM.

Global BioMedical Pte. Ltd. ("GBM") has converted 7,259 shares of Series A Convertible Preferred Stock into 1,120,170 shares of the common stock, par value $0.02 per share (the "Common Stock"), of Document Security Systems, Inc. (the "Issuer").

These securities were owned directly by GBM. Mr. Chan has dispositive control over the securities of the Issuer owned by GBM.

Global BioMedical Pte. Ltd. ("GBM") has converted 7,259 shares of Series A Convertible Preferred Stock into 1,120,170 shares of the common stock, par value $0.02 per share (the "Common Stock"), of Document Security Systems, Inc. (the "Issuer").

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the Common Stock of the Issuer at a conversion price of $6.48 per share. Following the conversion of 7,259 shares of Series A Convertible Preferred Stock, GBM does not own any shares of Series A Convertible Preferred Stock. Mr. Chan has dispositive control over the securities owned by GBM.

The beneficial ownership of the Reporting Person includes 10,036,164 shares of Common Stock, consisting of (a) 1,614,552 shares of Common Stock held by Heng Fai Holdings Limited; (b) 16,667 shares of Common Stock held by BMI Capital Partners International Limited; (c) 474,060 shares of Common Stock held by the Reporting Person; (d) 214,881 shares of Common Stock held by LiquidValue Development Pte Ltd.; and (e) 7,716,004 shares of Common Stock held by Global Biomedical Pte. Ltd.

These securities were owned directly by GBM. Mr. Chan has dispositive control over the securities of the Issuer owned by GBM.

The beneficial ownership of the Reporting Person includes, in addition to those purchases described herein, 7,392,012 shares of common stock, par value $0.02 per share, of Document Security Systems, Inc. ("Common Stock"), consisting of (a) 59,552 shares of Common Stock held by Heng Fai Holdings Limited; (b) 16,667 shares of Common Stock held by BMI Capital Partners International Limited; (c) 474,060 shares of Common Stock held by the Reporting Person; (d) 214,881 shares of Common Stock held by LiquidValue Development Pte Ltd.; and (e) (i) 6,595,834 shares of Common Stock and (ii) 31,018 shares of Common Stock that could be obtained upon the conversion of shares of Series A Convertible Preferred Stock, par value $.02 per share, beneficially owned by the Reporting Person, held by Global Biomedical Pte. Ltd.

The beneficial ownership of the Reporting Person includes, in addition to those purchases described herein, 7,392,012 shares of common stock, par value $0.02 per share, of Document Security Systems, Inc. ("Common Stock"), consisting of (a) 59,552 shares of Common Stock held by Heng Fai Holdings Limited; (b) 16,667 shares of Common Stock held by BMI Capital Partners International Limited; (c) 474,060 shares of Common Stock held by the Reporting Person; (d) 214,881 shares of Common Stock held by LiquidValue Development Pte Ltd.; and (e) (i) 6,595,834 shares of Common Stock and (ii) 31,018 shares of Common Stock that could be obtained upon the conversion of shares of Series A Convertible Preferred Stock, par value $.02 per share, beneficially owned by the Reporting Person, held by Global Biomedical Pte. Ltd.

The beneficial ownership of the Reporting Person includes, in addition to those purchases described herein, 7,392,012 shares of common stock, par value $0.02 per share, of Document Security Systems, Inc. ("Common Stock"), consisting of (a) 59,552 shares of Common Stock held by Heng Fai Holdings Limited; (b) 16,667 shares of Common Stock held by BMI Capital Partners International Limited; (c) 474,060 shares of Common Stock held by the Reporting Person; (d) 214,881 shares of Common Stock held by LiquidValue Development Pte Ltd.; and (e) (i) 6,595,834 shares of Common Stock and (ii) 31,018 shares of Common Stock that could be obtained upon the conversion of shares of Series A Convertible Preferred Stock, par value $.02 per share, beneficially owned by the Reporting Person, held by Global Biomedical Pte. Ltd.

Global BioMedical Pte. Ltd. ("GBM") has converted 35,316 shares of Series A Convertible Preferred Stock into 5,450,000 shares of the common stock of Document Security Systems, Inc. (the "Issuer").

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the common stock of the Issuer at a conversion price of $6.48 per share, subject to a 19.99% beneficial ownership conversion limitation (the "Blocker") based on the total issued and outstanding shares of common stock of the Issuer beneficially owned by GBM. There are currently 33,120,125 shares of the Issuer's common stock issued and outstanding, and therefore, as a result of the Blocker, GBM is currently able to convert an additional 201 shares of Series A Preferred Stock, equal to 31,018 shares of the Issuer's common stock. Mr. Chan has dispositive control over the securities owned by GBM.

These securities are owned directly by GBM. Mr. Chan has dispositive control over the common stock and Series A Convertible Preferred Stock of the Issuer owned by GBM.

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the common stock of the Issuer at a conversion price of $6.48 per share, subject to a 19.99% beneficial ownership conversion limitation (the "Blocker") based on the total issued and outstanding shares of common stock of the Issuer beneficially owned by GBM. There are currently 33,120,125 shares of the Issuer's common stock issued and outstanding, and therefore, as a result of the Blocker, GBM is currently able to convert an additional 201 shares of Series A Preferred Stock, equal to 31,018 shares of the Issuer's common stock. Mr. Chan has dispositive control over the securities owned by GBM.

Global BioMedical Pte. Ltd. ("GBM") has converted 35,316 shares of Series A Convertible Preferred Stock into 5,450,000 shares of the common stock of Document Security Systems, Inc. (the "Issuer").

These securities are owned directly by GBM. Mr. Chan has dispositive control over the common stock and Series A Convertible Preferred Stock of the Issuer owned by GBM.

Global BioMedical Pte. Ltd. ("GBM") has converted 4,293 shares of Series A Convertible Preferred Stock into 662,500 shares of the common stock of Document Security Systems, Inc. (the "Issuer").

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the common stock of the Issuer at a conversion price of $6.48 per share, subject to a 19.99% beneficial ownership conversion limitation (the "Blocker") based on the total issued and outstanding shares of common stock of the Issuer beneficially owned by GBM. There are currently 5,836,212 shares of the Issuer's common stock issued and outstanding, and therefore, as a result of the Blocker, GBM is currently able to convert an additional 168 shares of Series A Preferred Stock, equal to 25,925 shares of the Issuer's common stock. Mr. Chan has dispositive control over the securities owned by GBM.

These securities are owned directly by GBM. Mr. Chan has dispositive control over the common stock and Series A Convertible Preferred Stock of the Issuer owned by GBM.

The Series A Convertible Preferred Stock of the Issuer has a stated value of $1,000 per share and may be converted into shares of the common stock of the Issuer at a conversion price of $6.48 per share, subject to a 19.99% beneficial ownership conversion limitation (the "Blocker") based on the total issued and outstanding shares of common stock of the Issuer beneficially owned by GBM. There are currently 5,836,212 shares of the Issuer's common stock issued and outstanding, and therefore, as a result of the Blocker, GBM is currently able to convert an additional 168 shares of Series A Preferred Stock, equal to 25,925 shares of the Issuer's common stock. Mr. Chan has dispositive control over the securities owned by GBM.

Global BioMedical Pte. Ltd. ("GBM") has converted 4,293 shares of Series A Convertible Preferred Stock into 662,500 shares of the common stock of Document Security Systems, Inc. (the "Issuer").

These securities are owned directly by GBM. Mr. Chan has dispositive control over the common stock and Series A Convertible Preferred Stock of the Issuer owned by GBM.

On August 21, 2020, Document Security Systems, Inc., a New York corporation (the "Issuer") closed on a share exchange agreement (the "Exchange Agreement") by and among the Issuer, DSS BioHealth Security, Inc., Singapore eDevelopment Ltd. ("SeD"), an entity controlled by the Reporting Person, and Global Biomedical Pte Ltd. ("GBM"), a wholly-owned subsidiary of SeD. Pursuant to the Exchange Agreement, GBM received 483,334 shares of the Issuer's common stock at a per share cost basis of $6.48 per share. The Reporting Person has dispositive control over these securities.

In connection with the Exchange Agreement, GBM received 46,868 newly issued shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred Stock") with a stated value of $46,868,000, or $1,000 per share. The Series A Preferred Stock is convertible into shares of common stock of DSS, at an initial conversion price of $6.48 per share, subject to a 19.9% beneficial ownership conversion limitation ("Blocker") based on the total issued and outstanding shares of common stock of the Issuer beneficially owned by GBM. As of August 21, 2020, there were 5,115,179 shares of the Issuer's common stock issued and outstanding, and therefore, as a result of the Blocker, GBM is currently only able to convert the number of Series A Preferred Stock equal to approximately 673,904 shares of the Issuer's common stock, or approximately 4,366 shares of Series A Preferred Stock. The Reporting Person has dispositive control over these securities.

The original Form 4 filed on February 27, 2020 is amended by this Form 4 amendment to correctly reflect the reporting person's ownership of Common Stock. No other changes have been made to the original Form 4.

On February 24, 2020, the Reporting Persons purchased from the Issuer 11,111,112 shares of the Issuer's Common Stock, in an underwritten public offering, in consideration for $2,000,000.

Represents a restricted stock grant awarded to the Reporting Person by the Issuer pursuant to the Executive Employment Agreement between the Issuer and the Reporting Person and the Issuer's 2020 Equity Incentive Plan, in consideration for the Reporting Person's services as Executive Chairman of the Issuer and Executive Chairman and Chief Executive Officer of the Issuer's subsidiary.